Home > Boards > US Listed > Medical - Equipment > Itamar Medical Ltd. (ITMR)

Just had a look at this and I

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 17
Posts 974
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 12/16/2021 4:11:41 PM
Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse) Edgar (US Regulatory) - 12/16/2021 8:42:15 AM
Itamar Medical EPS beats by $0.23, beats on revenue Seeking Alpha - 11/18/2021 6:24:10 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/18/2021 6:04:28 AM
Itamar Medical Reports Third Quarter 2021 Financial Results GlobeNewswire Inc. - 11/18/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 11/16/2021 4:06:47 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 10/14/2021 5:21:24 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 10/4/2021 6:05:02 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 9/13/2021 5:28:31 PM
ATER, AXTI and OIIM among mid-day movers Seeking Alpha - 9/13/2021 1:25:44 PM
Amended Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k/a) Edgar (US Regulatory) - 8/12/2021 8:25:03 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:36:47 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 8/12/2021 6:31:21 AM
Itamar Medical Appoints Marga Ortigas-Wedekind to its Board of Directors GlobeNewswire Inc. - 8/12/2021 6:00:00 AM
Itamar Medical Reports Second Quarter 2021 Financial Results GlobeNewswire Inc. - 8/10/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 7/28/2021 6:08:19 AM
Itamar Medical to Report Second Quarter Financial Results and Host Conference Call on Tuesday, August 10, 2021 GlobeNewswire Inc. - 7/28/2021 6:00:00 AM
Teleflex and Itamar sell off “too draconian”: Piper Sandler Seeking Alpha - 7/16/2021 4:57:40 PM
Itamar Medical to Present at the Ladenburg Thalmann Annual Healthcare Conference on Wednesday, July 14, 2021 GlobeNewswire Inc. - 6/30/2021 6:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 6/17/2021 11:07:41 AM
Itamar Medical Launches Enhancements to WatchPAT™ Product Line at SLEEP 2021 GlobeNewswire Inc. - 6/7/2021 6:00:00 AM
Itamar Medical Appoints Brad Fluegel to its Board of Directors GlobeNewswire Inc. - 5/24/2021 6:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 5/20/2021 6:09:20 AM
Itamar Medical EPADS beats by $0.01, beats on revenue Seeking Alpha - 5/19/2021 6:03:06 AM
Itamar Medical Reports First Quarter 2021 Results GlobeNewswire Inc. - 5/19/2021 6:00:00 AM
Spideyboy   Tuesday, 06/23/20 05:22:15 AM
Re: None
Post # of 12 
Just had a look at this and I think the product will do what it says it can do and makes sense from the scientific perspective.

However I see both positive and negatives.

Positive is that the product makes it possible for patients to use the device at home and thus make more frequent observations.

Also sleep apnea is increasing as the levels of obesity continued to increase which doesn't look like will slow down.

The negative is that normal sleep laboratories take quite a few more data points that this product can't do, particularly regards airflow and the measurement of chest movement in 2 different places, as well as REM eye movements, which are important. The additional data points can better help diagnose the sleep issue at hand. Hence my concern would be that once normal sleep laboratories open, how many physicians will keep using this product with less data points. For a physician the more data the better. And then there is the analysis, which for product seems to be done by computer while sleep labs still use qualified technicians to identify issues. Can't say if one is better than the other though.

Possible that if the oxygenation levels are accurately measure with the product they might be ok with dispensing with airflow but again more data is better.

I see they note on the website that their product has 89% correlations with polysomnography and 98% study success rate, but those facts come from only 2 sources which is not particularly convincing.

So once sleep labs are fully open and operational what will that mean for the product?

An interesting one to look at though and will add to my watch list.

Will give BWAY a look at soon too!

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences